Product Description
Mechanisms of Action: Lithium
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Medesis Pharma SA
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for NanoLithium® NP03](https://pryzm-maps.s3.us-west-2.amazonaws.com/25current_maps.png)
Countries in Clinic: France
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NanoLi®_AD | P2 |
Recruiting |
Alzheimer Disease |
2024-01-23 |